Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.81 |
| ▸ | PIK3CA | P42336 | 20/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.81 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | PRKDC | P78527 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715348 | 0.93 | PIK3CD (0.85) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29370516 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL323054 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL323055 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30089313 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| SCHEMBL25485898 | 0.89 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789594 | 0.89 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789551 | 0.89 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789521 | 0.89 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| SCHEMBL322225 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.